Healthcare companies Sanofi and Regeneron announced on Friday that the European Union's medicines regulator had given a new stage of approval for their Dupixent product to treat children as young as six months old with severe atopic dermatitis.
The European Commission is expected to announce a final decision on the Dupixent application in the coming months, while in June 2022 Dupixent had already been approved by the U.S. Food and Drug Administration (FDA) regulator for children in this age group.
https://finance.yahoo.com/news/sanofi-regeneron-dupixent-wins-stage-060811153.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.